Skip to main content
SpringerLink
Log in

Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy

  • Original Articles
  • Levonantradol Antiemetic
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

Levonantradol, a new antiemetic compound pharmacologically related to the cannabinoids, was given to 17 patients who had experienced severe and protracted nausea and vomiting during previous courses of cancer chemotherapy, and to six patients receiving a first course of strongly emetic cytostatic treatment. Eight patients were partially protected from acute gastrointestinal disturbances. Of the 23 patients, 21 exhibited some toxicity, with six patients exhibiting major affective side-effects and 13 patients complaining of pain at the injection site. Levonantradol is an active antiemetic compound. Due to the rate of side-effects observed in our study however, we would not recommend use of this agent as an antiemetic drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cronin CM, Sallan SE (1981) Early results of the antiemetic activity of intramuscular levonantradol. In: Poster DS, Penta JS, Bruno S (eds) Treatment of cancer chemotherapy-induced nausea and vomiting. Masson, New York, p 137

    Google Scholar 

  2. Gralla RJ, Itri LM, Pisko SE, Squillante AE, Kelsen DP, Braun DW, Bordin LA, Braun TJ, Young CW (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305: 905

    Google Scholar 

  3. Heim ME, Romer W, Queisser W (1981) Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting. J Clin Pharmacol 21: 865

    Google Scholar 

  4. Hermann TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE (1979) Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med 300: 1295

    Google Scholar 

  5. Higi M, Niederle N, Bremer K, Seeber S (1981) Antiemetic efficacy of the new tetrahydrocannabinol-derivative levonantradol in patients receiving cancer chemotherapy. In: Book of conference abstracts. UICC Conference on Clinical Oncology, Lausanne, p 55

  6. Joss R, Galeazzi R, Gervasi A, Godat F, Goldhirsch A, Brunner KW (1981) Nausea und Erbrechen bei der Chemotherapie maligner Tumoren. Schweiz Med Wochenschrift 111: 1614

    Google Scholar 

  7. Kenny J, Wilkinson PM (1981) Antiemetic activity of levonantradol in chemotherapy-induced emesis. In: Book of conference abstract, UICC Conference on Clinical Oncology, Lausanne, p 57

  8. Pfizer Central Research (1981) Investigator's Reference Manual on Levonantradol

  9. Poster DS, Penta JS, Bruno S, Mac Donald JS (1981) Δ9-Tetrahydrocannabinol in clinical oncology. JAMA 245: 2047

    Google Scholar 

  10. Schulz LW (1980) Classical (pavlovian) conditioning of nausea and vomiting in cancer chemotherapy. Proc Am Soc Clin Oncol 21: 381

    Google Scholar 

  11. Smith IE, Stuart-Harris R (1981) Levonantradol, a cannabinoid-related agent in the treatment of intractable chemotherapy-induced nausea and vomiting: a phase 2 study. In: Book of conference abstracts. UICC Conference on Clinical Oncology, Lausanne, p 56

  12. Staquet M, Bron D, Rozencweig M, Kenis Y (1981) Clinical studies with a THC analog (BRL-4664) in the prevention of cis-platin-induced vomiting. J Clin Pharmacol 21: 604

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Medical Oncology, University of Berne, CH-3010, Berne, Switzerland

    Rudolf A. Joss & Kurt W. Brunner

  2. Department of Internal Medicine, University of Berne, CH-3010, Berne, Switzerland

    Renato L. Galeazzi & Annakatharina Bischoff

  3. Ludwig Institute for Cancer Research, University of Berne, CH-3010, Berne, Switzerland

    Do D. Do & Aron Goldhirsch

Authors
  1. Rudolf A. Joss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renato L. Galeazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Annakatharina Bischoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Do D. Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Aron Goldhirsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kurt W. Brunner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Joss, R.A., Galeazzi, R.L., Bischoff, A. et al. Levonantradol, a new antiemetic with a high rate of side-effects for the prevention of nausea and vomiting in patients receiving cancer chemotherapy. Cancer Chemother. Pharmacol. 9, 61–64 (1982). https://doi.org/10.1007/BF00296765

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00296765

Keywords

Search

Navigation